Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66, HorseShoe Man
Search This Board:
Last Post: 2/13/2016 3:07:23 AM - Followers: 553 - Board type: Free - Posts Today: 1

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Quarterly Report (10-q) 10/15/2015 06:07:03 AM
#41177   $MCET Chart $Pistol Pete$ 02/13/16 03:07:23 AM
#41176   That's ok, I have glasses and still miss thetruth63 02/10/16 07:38:21 PM
#41175   I stand corrected, sorry. Guess I do need glasses.. ctvette2003 02/10/16 07:32:20 PM
#41174   must have missed a gear vette. Its been thetruth63 02/10/16 07:26:40 PM
#41172 TraderpennyX 02/10/16 07:13:17 PM
#41171   No mention of OXIS or MCET and no ctvette2003 02/10/16 06:54:27 PM
#41170 LOS ANGELES, Feb. 10, 2016 HorseShoe Man 02/10/16 04:17:52 PM
#41169   think you replied to the wrong person? I ctvette2003 02/10/16 04:16:12 PM
#41168   I am sure they call it a triumph! simon wagstaff 02/10/16 04:11:14 PM
#41167   Horse which PR says they killed a ctvette2003 02/10/16 03:05:33 PM
#41166   OXIS is calling phase 1 a triumph! It HorseShoe Man 02/10/16 01:07:13 PM
#41165   Could you imagine how fast MCET will move HorseShoe Man 02/10/16 12:46:51 PM
#41164   OXIS/MCET killed a tumor completely according to OXIS. HorseShoe Man 02/10/16 12:36:50 PM
#41163   10K at end of month. MyDogBuster 02/09/16 11:50:18 PM
#41161   Good to see you here Pete…Do you see ferenc 02/09/16 10:44:47 PM
#41160   Inst there a 10Q due? ctvette2003 02/08/16 08:48:14 PM
#41159   FLOAT 4.4B NOT 600K, please post accurate info ctvette2003 02/03/16 04:17:57 AM
#41158   Pete you must be board, this stock is ctvette2003 02/03/16 04:16:22 AM
#41157   $MCET ~ MultiCell Technologies, Inc. due diligence repor $Pistol Pete$ 02/02/16 07:15:19 PM
#41156   none sense attachment eshety 01/30/16 03:54:08 PM
#41155   Volume picking up. The dead cat bouncer 01/29/16 12:40:29 PM
#41153   LMAO hell no, I was busting on Horse ctvette2003 01/20/16 04:29:49 PM
#41152   Halted? This is high volume, $600 traded. simon wagstaff 01/20/16 04:26:39 PM
#41151   Horse do you think we have been halted ctvette2003 01/20/16 10:44:40 AM
#41150   board updated Dip66 01/20/16 12:26:42 AM
#41149   nice volume today. The dead cat bouncer 01/19/16 09:03:01 PM
#41148   yes I done did it . . . bontooth 01/16/16 03:48:33 AM
#41147   Biotech Exec Took A Company From $2 to redsox17 01/13/16 07:23:57 AM
#41146   No - Next is 10K and it usually MyDogBuster 01/12/16 09:40:14 AM
#41145   The 10Q is due in 3 days. ferenc 01/12/16 09:08:47 AM
#41144   you guys are crazy. the newmins are crazy. bontooth 01/10/16 03:28:39 AM
#41143   Horse was making his normal posts and I ctvette2003 01/08/16 02:16:49 PM
#41142   huh when did it halt? sup105 01/08/16 01:52:22 PM
#41141   Guess the halt was lifted LMFAO ctvette2003 01/06/16 05:28:16 PM
#41140   Looks like a paid marketing campaign, they are ctvette2003 01/06/16 05:01:39 AM
#41139   no. closed out all my positions in everything. bontooth 01/06/16 02:29:00 AM
#41138 Dip66 01/05/16 10:05:04 PM
#41137   Still waiting for that link?? ctvette2003 01/05/16 05:31:25 PM
#41136   Horse you have a link to the Halt ctvette2003 01/05/16 03:23:51 PM
#41135   SEC freezes trading on M _ _ _ HorseShoe Man 01/05/16 01:36:16 PM
#41134   Not even trading anymore? HorseShoe Man 01/05/16 11:24:16 AM
#41133   we could not see any sign of hope eshety 01/04/16 08:42:42 PM
#41132   Same to you buddy HorseShoe Man 01/01/16 07:36:13 AM
#41131   Good luck next year to you sir. The dead cat bouncer 12/31/15 05:52:14 PM
#41130   OXIS is expecting a big PR after the HorseShoe Man 12/31/15 09:09:46 AM
#41129   yes it is Horse, we're DUMPING bontooth 12/28/15 07:01:07 PM
#41128   Very interesting trading? !! HorseShoe Man 12/28/15 03:26:10 PM
#41127   just shut this down already and stop torturing Dip66 12/25/15 08:28:01 AM
#41126   Can't Complain . . MCET Barb bought me bontooth 12/25/15 12:24:30 AM